As reported by PharmaLeaks*, Alnylam Pharmaceuticals (NASDAQ: ALNY) is once again facing regulatory scrutiny from the U.S. Food and Drug Administration (FDA) over promotional claims tied to its heart drug Amvuttra.
The FDA recently issued a cease-and-desist letter to the biotechnology company, alleging that statements published on Amvuttra’s website may mislead patients and healthcare audiences about the drug’s effectiveness. The agency has instructed Alnylam to respond by 14 May with details on how it intends to address the concerns.
Amvuttra is approved for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM), a rare and progressive heart disease. According to the FDA, several promotional statements on the drug’s website overstated the medication’s demonstrated benefits, particularly around survival outcomes.
Among the claims cited by regulators were suggestions that the therapy was “proven” to help patients live longer and that continued treatment reduced the risk of death over several years. The FDA concluded that the messaging could create an inaccurate impression regarding the extent of the drug’s clinical benefit.
The enforcement action reflects a broader shift in the FDA’s approach to pharmaceutical marketing oversight. Since late 2025, the agency has signaled a more aggressive posture toward drug advertising and promotional materials, particularly in digital and direct-to-consumer channels.
Regulators have increasingly focused on how pharmaceutical companies communicate benefits and risks online, including company websites, social media campaigns, and telehealth-related promotions. In recent months, the FDA has also targeted businesses promoting compounded versions of high-demand weight-loss medications.
For Alnylam, the latest warning is not an isolated incident. The company previously drew FDA attention in 2025 over a television advertisement for Amvuttra that portrayed patients engaging in activities such as travel and recreational outings. Regulators argued that the campaign risked minimizing the seriousness of the underlying disease while presenting an overly optimistic portrayal of treatment outcomes. The advertisement was later withdrawn following FDA feedback.
Industry observers are expected to watch Alnylam’s response closely. Beyond the company itself, the outcome may offer an early indication of how seriously pharmaceutical manufacturers are taking the FDA’s renewed focus on promotional compliance.
The case also highlights a growing tension across the pharmaceutical industry: balancing competitive marketing strategies with increasingly strict regulatory expectations around patient-facing communications.
*Additional reporting and pharmaceutical industry investigations are available through PharmaLeaks, a platform focused on exposing underreported developments and regulatory issues within the global drug industry.
